Mangalam Drugs and Organics Ltd

Mangalam Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mangalam Drugs and Organics Ltd

₹ 25.2 0.52%
12 Dec - close price
mangalamdrugs.com BSE: 532637 NSE: MANGALAM
About

Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]

Key Points

Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations

Website BSE NSE
  • Market Cap ₹ 39.9 Cr.
  • Current Price ₹ 25.2
  • High / Low ₹ 130 / 23.6
  • Stock P/E
  • Book Value ₹ 80.6
  • Dividend Yield 0.00 %
  • ROCE 8.05 %
  • ROE 4.68 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.31 times its book value

Cons

  • Company has low interest coverage ratio.
  • Contingent liabilities of Rs.34.6 Cr.
  • Promoters have pledged or encumbered 34.6% of their holding.
  • Debtor days have increased from 36.2 to 44.8 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
97.34 102.24 76.53 79.94 88.71 73.04 57.35 49.54
90.36 90.55 68.34 71.24 79.94 62.88 61.83 52.38
Operating Profit 6.98 11.69 8.19 8.70 8.77 10.16 -4.48 -2.84
OPM % 7.17% 11.43% 10.70% 10.88% 9.89% 13.91% -7.81% -5.73%
0.00 0.05 0.02 0.14 0.14 0.21 0.00 0.03
Interest 3.31 3.95 3.75 3.67 3.49 4.03 4.04 5.03
Depreciation 3.63 3.86 3.88 3.97 4.05 4.70 4.48 4.63
Profit before tax 0.04 3.93 0.58 1.20 1.37 1.64 -13.00 -12.47
Tax % -1,150.00% 10.18% -362.07% -124.17% 5.84% 95.73% 6.15% -41.06%
0.50 3.53 2.68 2.69 1.29 0.06 -13.80 -7.35
EPS in Rs 0.32 2.23 1.69 1.70 0.82 0.04 -8.72 -4.64
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 TTM
369 318 269
351 282 257
Operating Profit 17 36 12
OPM % 5% 11% 4%
0 0 0
Interest 14 15 17
Depreciation 15 17 18
Profit before tax -11 5 -22
Tax % -18% -41%
-9 7 -20
EPS in Rs -5.73 4.25 -12.50
Dividend Payout % 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -25%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -311%
Stock Price CAGR
10 Years: -22%
5 Years: -29%
3 Years: -43%
1 Year: -79%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025 Sep 2025
Equity Capital 16 16 16
Reserves 120 133 112
107 96 95
91 121 94
Total Liabilities 334 366 317
148 163 159
CWIP 8 3 4
Investments 0 0 0
178 201 155
Total Assets 334 366 317

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
4 43
-12 -19
5 -22
Net Cash Flow -3 1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2024 Mar 2025
Debtor Days 28 45
Inventory Days 185 303
Days Payable 99 199
Cash Conversion Cycle 113 149
Working Capital Days 11 5
ROCE % 8%

Shareholding Pattern

Numbers in percentages

40 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.31% 50.30% 50.30% 50.30% 50.30% 50.30%
0.10% 0.10% 0.10% 0.10% 0.10% 0.26% 0.21% 0.11% 0.11% 0.47% 0.53% 0.11%
49.58% 49.59% 49.58% 49.59% 49.59% 49.42% 49.47% 49.58% 49.58% 49.23% 49.16% 49.57%
No. of Shareholders 17,91117,94317,89017,97818,61019,17319,31219,50819,67919,69719,72819,881

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls

  • Aug 2016
    Transcript
    AI Summary
    PPT
  • May 2016
    Transcript
    AI Summary
    PPT
  • Feb 2016
    Transcript
    AI Summary
    PPT